Search

Displaying results 1911 - 1920 of 4539 in total
  1. Drug

    Pivhydrazine

    go.drugbank.com/drugs/DB09252
    ApprovedWithdrawn

    In 1960, it was widely used as an antidepressant agent but it is now discontinued.

  2. Drug

    Entecavir

    go.drugbank.com/drugs/DB00442
    ApprovedInvestigational

    It was approved by the U.S. Food and Drug Administration (FDA) in March 2005.

  3. Drug

    Ceftizoxime

    go.drugbank.com/drugs/DB01332
    ApprovedWithdrawn

    A semisynthetic cephalosporin antibiotic which can be administered intravenously or by suppository.

  4. Drug

    Phenoxypropazine

    go.drugbank.com/drugs/DB09251
    ApprovedWithdrawn

    It was marketed as an antidepressant in 1961 but was later withdrawn in 1966 because of its hepatotoxic potential.

  5. Drug

    Tabelecleucel

    go.drugbank.com/drugs/DB17072
    ApprovedInvestigational

    It is produced by mixing T-cells with B-cells that have been infected with the Epstein-Barr virus (EBV).

  6. Drug

    GALE-301

    go.drugbank.com/drugs/DB17262
    Investigational

    It is made up of E39, an immunogenic peptide derived from the folate binding protein (FBP), and an immune adjuvant, granulocyte macrophage-colony stimulating factor (GM-CSF).[A254696,L44166,L44171]

  7. Drug

    Anastrozole

    go.drugbank.com/drugs/DB01217
    ApprovedInvestigational

    [L8863] Anastrozole is also related to [exemestane], a steroidal AI, but its non-steroidal nature provides stark advantages including a lack of steroid-associated adverse effects such as weight gain and

  8. Drug

    DP-VPA

    go.drugbank.com/drugs/DB05821
    Investigational

    DP-VPA is D-Pharm's proprietary lipid modified version of valproic acid (VPA) that demonstrate that DP-VPA is well-tolerated in patients with resistant epilepsy and has a marked effect on reducing seizure frequency.

  9. Drug

    Vadadustat

    go.drugbank.com/drugs/DB12255
    ApprovedInvestigational

    [L39610,L46936,L46951] Vadadustat was approved by the FDA in March 2024.[L50371] … One of the most common symptoms of advanced renal disease is anemia, caused primarily by the inability of the kidney to respond to anemic conditions with a corresponding increase in [erythropoietin] (EPO

  10. Drug

    Tolazamide

    go.drugbank.com/drugs/DB00839
    Approved

    A sulphonylurea hypoglycemic agent with actions and uses similar to those of chlorpropamide.